| pubmed-article:17223858 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17223858 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:17223858 | lifeskim:mentions | umls-concept:C0033618 | lld:lifeskim |
| pubmed-article:17223858 | lifeskim:mentions | umls-concept:C0007546 | lld:lifeskim |
| pubmed-article:17223858 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:17223858 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:17223858 | pubmed:dateCreated | 2007-5-18 | lld:pubmed |
| pubmed-article:17223858 | pubmed:abstractText | The aims of the study were a) to determine if there is evidence of saturable protein binding of cefazolin in plasma across the range of concentrations achieved clinically (between patient variability) and b) to investigate whether saturable protein binding is also evident from trough and peak concentrations in the same patient (within patient variability). | lld:pubmed |
| pubmed-article:17223858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17223858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17223858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17223858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17223858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17223858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17223858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17223858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17223858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17223858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17223858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17223858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17223858 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17223858 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17223858 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17223858 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17223858 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17223858 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17223858 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17223858 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:17223858 | pubmed:issn | 0306-5251 | lld:pubmed |
| pubmed-article:17223858 | pubmed:author | pubmed-author:ZhangMeiM | lld:pubmed |
| pubmed-article:17223858 | pubmed:author | pubmed-author:KirkpatrickCa... | lld:pubmed |
| pubmed-article:17223858 | pubmed:author | pubmed-author:BeggEvan JEJ | lld:pubmed |
| pubmed-article:17223858 | pubmed:author | pubmed-author:ChambersSteph... | lld:pubmed |
| pubmed-article:17223858 | pubmed:author | pubmed-author:GallagherKate... | lld:pubmed |
| pubmed-article:17223858 | pubmed:author | pubmed-author:Vella-Brincat... | lld:pubmed |
| pubmed-article:17223858 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17223858 | pubmed:volume | 63 | lld:pubmed |
| pubmed-article:17223858 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17223858 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17223858 | pubmed:pagination | 753-7 | lld:pubmed |
| pubmed-article:17223858 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:17223858 | pubmed:meshHeading | pubmed-meshheading:17223858... | lld:pubmed |
| pubmed-article:17223858 | pubmed:meshHeading | pubmed-meshheading:17223858... | lld:pubmed |
| pubmed-article:17223858 | pubmed:meshHeading | pubmed-meshheading:17223858... | lld:pubmed |
| pubmed-article:17223858 | pubmed:meshHeading | pubmed-meshheading:17223858... | lld:pubmed |
| pubmed-article:17223858 | pubmed:meshHeading | pubmed-meshheading:17223858... | lld:pubmed |
| pubmed-article:17223858 | pubmed:meshHeading | pubmed-meshheading:17223858... | lld:pubmed |
| pubmed-article:17223858 | pubmed:meshHeading | pubmed-meshheading:17223858... | lld:pubmed |
| pubmed-article:17223858 | pubmed:meshHeading | pubmed-meshheading:17223858... | lld:pubmed |
| pubmed-article:17223858 | pubmed:meshHeading | pubmed-meshheading:17223858... | lld:pubmed |
| pubmed-article:17223858 | pubmed:meshHeading | pubmed-meshheading:17223858... | lld:pubmed |
| pubmed-article:17223858 | pubmed:meshHeading | pubmed-meshheading:17223858... | lld:pubmed |
| pubmed-article:17223858 | pubmed:meshHeading | pubmed-meshheading:17223858... | lld:pubmed |
| pubmed-article:17223858 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17223858 | pubmed:articleTitle | Protein binding of cefazolin is saturable in vivo both between and within patients. | lld:pubmed |
| pubmed-article:17223858 | pubmed:affiliation | Department of Clinical Pharmacology, Christchurch Hospital, Christchurch, New Zealand. | lld:pubmed |
| pubmed-article:17223858 | pubmed:publicationType | Journal Article | lld:pubmed |
